Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0001883850-23-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-02-08 | 2023-02-06 | REGN | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $800.08 | -13.2K | 200.5K | -6% | -$10.55M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | S | D | 13,189 | $800.08 | 200,504 | I By Trust for Chldn. | — | — | (F2) Represents volume-weighted average price of sales of 13,189 shares of Company stock on February 6, 2023 at prices ranging from $800.00 to $800.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. (F3) As investment trustee of trusts for the benefit of the reporting person's children. |